E
Virpax Pharmaceuticals, Inc.
VRPX
$0.6695
-$0.5505-45.12%
E
Sell
12/26/2023Downgrade
Virpax Pharmaceuticals, Inc. (VRPX) was downgraded to E+ from D- on 12/26/2023 due to a decline in the volatility index and total return index.
Virpax Pharmaceuticals, Inc. (VRPX) was downgraded to E+ from D- on 12/26/2023 due to a decline in the volatility index and total return index.
D
Sell
12/8/2023Upgraded
Virpax Pharmaceuticals, Inc. (VRPX) was upgraded to D- from E+ on 12/8/2023 due to an increase in the volatility index, growth index and valuation index.
Virpax Pharmaceuticals, Inc. (VRPX) was upgraded to D- from E+ on 12/8/2023 due to an increase in the volatility index, growth index and valuation index.
E
Sell
11/27/2023Downgrade
Virpax Pharmaceuticals, Inc. (VRPX) was downgraded to E+ from D- on 11/27/2023 due to a decline in the volatility index and total return index.
Virpax Pharmaceuticals, Inc. (VRPX) was downgraded to E+ from D- on 11/27/2023 due to a decline in the volatility index and total return index.
D
Sell
11/6/2023Upgraded
Virpax Pharmaceuticals, Inc. (VRPX) was upgraded to D- from E+ on 11/6/2023 due to an increase in the volatility index.
Virpax Pharmaceuticals, Inc. (VRPX) was upgraded to D- from E+ on 11/6/2023 due to an increase in the volatility index.
E
Sell
10/20/2023Downgrade
Virpax Pharmaceuticals, Inc. (VRPX) was downgraded to E+ from D- on 10/20/2023 due to a decline in the volatility index and total return index.
Virpax Pharmaceuticals, Inc. (VRPX) was downgraded to E+ from D- on 10/20/2023 due to a decline in the volatility index and total return index.
D
Sell
10/2/2023Upgraded
Virpax Pharmaceuticals, Inc. (VRPX) was upgraded to D- from E+ on 10/2/2023 due to an increase in the volatility index.
Virpax Pharmaceuticals, Inc. (VRPX) was upgraded to D- from E+ on 10/2/2023 due to an increase in the volatility index.
E
Sell
9/15/2023Downgrade
Virpax Pharmaceuticals, Inc. (VRPX) was downgraded to E+ from D- on 9/15/2023 due to a decline in the growth index, volatility index and solvency index. Earnings per share declined from -$0.1298 to -$0.2657, EBIT declined 82.03% from -$1.65M to -$3.01M, and the quick ratio declined from 5.16 to 4.06.
Virpax Pharmaceuticals, Inc. (VRPX) was downgraded to E+ from D- on 9/15/2023 due to a decline in the growth index, volatility index and solvency index. Earnings per share declined from -$0.1298 to -$0.2657, EBIT declined 82.03% from -$1.65M to -$3.01M, and the quick ratio declined from 5.16 to 4.06.
D
Sell
8/7/2023Upgraded
Virpax Pharmaceuticals, Inc. (VRPX) was upgraded to D- from E+ on 8/7/2023 due to a large increase in the growth index, volatility index and efficiency index. Earnings per share increased from -$0.255 to -$0.1298, and net income increased 49.1% from -$2.99M to -$1.52M.
Virpax Pharmaceuticals, Inc. (VRPX) was upgraded to D- from E+ on 8/7/2023 due to a large increase in the growth index, volatility index and efficiency index. Earnings per share increased from -$0.255 to -$0.1298, and net income increased 49.1% from -$2.99M to -$1.52M.
E
Sell
11/16/2022Downgrade
Virpax Pharmaceuticals, Inc. (VRPX) was downgraded to E+ from D- on 11/16/2022 due to a decline in the solvency index, volatility index and growth index. The quick ratio declined from 10.49 to 4.89, EBIT declined 30.67% from -$5.9M to -$7.72M, and earnings per share declined from -$0.5024 to -$0.6524.
Virpax Pharmaceuticals, Inc. (VRPX) was downgraded to E+ from D- on 11/16/2022 due to a decline in the solvency index, volatility index and growth index. The quick ratio declined from 10.49 to 4.89, EBIT declined 30.67% from -$5.9M to -$7.72M, and earnings per share declined from -$0.5024 to -$0.6524.
D
Sell
11/3/2022Upgraded
Virpax Pharmaceuticals, Inc. (VRPX) was upgraded to D- from E+ on 11/3/2022 due to an increase in the volatility index.
Virpax Pharmaceuticals, Inc. (VRPX) was upgraded to D- from E+ on 11/3/2022 due to an increase in the volatility index.
E
Sell
10/19/2022Downgrade
Virpax Pharmaceuticals, Inc. (VRPX) was downgraded to E+ from D- on 10/19/2022 due to a decline in the volatility index and total return index.
Virpax Pharmaceuticals, Inc. (VRPX) was downgraded to E+ from D- on 10/19/2022 due to a decline in the volatility index and total return index.
D
Sell
10/3/2022Upgraded
Virpax Pharmaceuticals, Inc. (VRPX) was upgraded to D- from E+ on 10/3/2022 due to an increase in the volatility index and total return index.
Virpax Pharmaceuticals, Inc. (VRPX) was upgraded to D- from E+ on 10/3/2022 due to an increase in the volatility index and total return index.
E
Sell
9/16/2022Downgrade
Virpax Pharmaceuticals, Inc. (VRPX) was downgraded to E+ from D- on 9/16/2022 due to a decline in the volatility index.
Virpax Pharmaceuticals, Inc. (VRPX) was downgraded to E+ from D- on 9/16/2022 due to a decline in the volatility index.
D
Sell
8/18/2022Upgraded
Virpax Pharmaceuticals, Inc. (VRPX) was upgraded to D- from E+ on 8/18/2022 due to an increase in the volatility index and growth index. Operating cash flow increased 21.65% from -$6.04M to -$4.74M.
Virpax Pharmaceuticals, Inc. (VRPX) was upgraded to D- from E+ on 8/18/2022 due to an increase in the volatility index and growth index. Operating cash flow increased 21.65% from -$6.04M to -$4.74M.
E
Sell
5/23/2022Downgrade
Virpax Pharmaceuticals, Inc. (VRPX) was downgraded to E+ from D- on 5/23/2022 due to a decline in the growth index, volatility index and solvency index. Earnings per share declined from -$0.3498 to -$0.4387, EBIT declined 24.32% from -$4.12M to -$5.12M, and operating cash flow declined 22.81% from -$4.92M to -$6.04M.
Virpax Pharmaceuticals, Inc. (VRPX) was downgraded to E+ from D- on 5/23/2022 due to a decline in the growth index, volatility index and solvency index. Earnings per share declined from -$0.3498 to -$0.4387, EBIT declined 24.32% from -$4.12M to -$5.12M, and operating cash flow declined 22.81% from -$4.92M to -$6.04M.
D
Sell
5/18/2022Upgraded
Virpax Pharmaceuticals, Inc. (VRPX) was upgraded to D- from E+ on 5/18/2022 due to an increase in the volatility index and total return index.
Virpax Pharmaceuticals, Inc. (VRPX) was upgraded to D- from E+ on 5/18/2022 due to an increase in the volatility index and total return index.
E
Sell
5/3/2022Downgrade
Virpax Pharmaceuticals, Inc. (VRPX) was downgraded to E+ from D- on 5/3/2022 due to a decline in the total return index.
Virpax Pharmaceuticals, Inc. (VRPX) was downgraded to E+ from D- on 5/3/2022 due to a decline in the total return index.
D
Sell
4/18/2022Upgraded
Virpax Pharmaceuticals, Inc. (VRPX) was upgraded to D- from E+ on 4/18/2022 due to an increase in the growth index. Earnings per share increased from -$0.5349 to -$0.3498.
Virpax Pharmaceuticals, Inc. (VRPX) was upgraded to D- from E+ on 4/18/2022 due to an increase in the growth index. Earnings per share increased from -$0.5349 to -$0.3498.
E
Sell
1/21/2022Downgrade
Virpax Pharmaceuticals, Inc. (VRPX) was downgraded to E+ from D- on 1/21/2022 due to a substantial decline in the total return index, volatility index and growth index. Operating cash flow declined 163.84% from -$1.8M to -$4.74M, EBIT declined 40.96% from -$2.31M to -$3.25M, and earnings per share declined from -$0.4726 to -$0.5349.
Virpax Pharmaceuticals, Inc. (VRPX) was downgraded to E+ from D- on 1/21/2022 due to a substantial decline in the total return index, volatility index and growth index. Operating cash flow declined 163.84% from -$1.8M to -$4.74M, EBIT declined 40.96% from -$2.31M to -$3.25M, and earnings per share declined from -$0.4726 to -$0.5349.
D
Sell
11/3/2021Upgraded
Virpax Pharmaceuticals, Inc. (VRPX) was upgraded to D- from E+ on 11/3/2021 due to an increase in the total return index and valuation index.
Virpax Pharmaceuticals, Inc. (VRPX) was upgraded to D- from E+ on 11/3/2021 due to an increase in the total return index and valuation index.
E
Sell
10/1/2021Upgraded
Virpax Pharmaceuticals, Inc. (VRPX) was upgraded to E+ from E on 10/1/2021 due to a noticeable increase in the total return index, volatility index and growth index.
Virpax Pharmaceuticals, Inc. (VRPX) was upgraded to E+ from E on 10/1/2021 due to a noticeable increase in the total return index, volatility index and growth index.
E
Sell
8/11/2021Upgraded
Virpax Pharmaceuticals, Inc. (VRPX) was upgraded to E from E- on 8/11/2021 due to an increase in the growth index, solvency index and total return index. Operating cash flow increased 41.64% from -$3.08M to -$1.8M, earnings per share increased from -$0.6031 to -$0.4726, and EBIT increased 1.84% from -$2.35M to -$2.31M.
Virpax Pharmaceuticals, Inc. (VRPX) was upgraded to E from E- on 8/11/2021 due to an increase in the growth index, solvency index and total return index. Operating cash flow increased 41.64% from -$3.08M to -$1.8M, earnings per share increased from -$0.6031 to -$0.4726, and EBIT increased 1.84% from -$2.35M to -$2.31M.
E
Sell
7/29/2021Downgrade
Virpax Pharmaceuticals, Inc. (VRPX) was downgraded to E- from E on 7/29/2021 due to a noticeable decline in the volatility index.
Virpax Pharmaceuticals, Inc. (VRPX) was downgraded to E- from E on 7/29/2021 due to a noticeable decline in the volatility index.
E
Sell
7/14/2021Upgraded
Virpax Pharmaceuticals, Inc. (VRPX) was upgraded to E from E- on 7/14/2021 due to a significant increase in the solvency index, volatility index and total return index. The quick ratio increased from 0.02 to 4.65.
Virpax Pharmaceuticals, Inc. (VRPX) was upgraded to E from E- on 7/14/2021 due to a significant increase in the solvency index, volatility index and total return index. The quick ratio increased from 0.02 to 4.65.
E
Sell
5/12/2021None
Virpax Pharmaceuticals, Inc. (VRPX) was downgraded to E- from U on 05/12/2021.
Virpax Pharmaceuticals, Inc. (VRPX) was downgraded to E- from U on 05/12/2021.
NASDAQ
04/03/2025 4:00PM Eastern
Quotes delayed
